PX1 Research supplies laboratory-grade CJC-1295 (no DAC) 5mg/vial engineered specifically for precise in vitro and animal models investigating growth hormone secretagogue signaling. Synthesized under strict quality standards in the USA, each lot undergoes rigorous third-party analytical testing to guarantee sequence accuracy, purity, and minimal endotoxin burden.
PX1 Research supplies laboratory-grade CJC-1295 (no DAC) 5mg/vial engineered specifically for precise in vitro and animal models investigating growth hormone secretagogue signaling. Synthesized under strict quality standards in the USA, each lot undergoes rigorous third-party analytical testing to guarantee sequence accuracy, purity, and minimal endotoxin burden.
CJC-1295 (no DAC) 5mg/vial is a synthetic 29-amino acid peptide analog of endogenous Growth Hormone-Releasing Hormone (GHRH), specifically optimized for preclinical research investigating physiological growth hormone (GH) secretion patterns. By omitting the Drug Affinity Complex (DAC), this peptide delivers a rapid, pulsatile signal to pituitary somatotrophs without causing extended elevation of systemic baseline hormone levels.
In analytical and laboratory settings, CJC-1295 (no DAC) serves as a primary standard for evaluating GHRH receptor kinetics, intracellular cyclic AMP (cAMP) generation, and downstream insulin-like growth factor 1 (IGF-1) cascade activation. Researchers rely on high-purity CJC-1295 (no DAC) 5mg formulations to ensure reproducible experimental outcomes across cell culture and animal models.
Chemically identified as Modified GRF 1-29, CJC-1295 (no DAC) contains targeted amino acid substitutions at positions 2, 8, 15, and 27 compared to naturally occurring GHRH(1-29). These specific substitutions (D-Ala2, Gln8, Ala15, and Leu27) enhance enzymatic stability against dipeptidyl peptidase IV (DPP-IV) cleavage while maintaining full affinity for the physiological GHRH receptor.
Upon binding to the GHRH receptor on anterior pituitary somatotrophs, the compound stimulates the Gs protein-coupled receptor pathway. This triggers adenylate cyclase activation, raising intracellular cAMP concentration and activating protein kinase A (PKA). Preclinical models demonstrate that this cascade prompts voltage-gated calcium entry, leading to the exocytosis of pre-stored growth hormone granules in a distinct, physiological pulse rather than a tonic spill.
Understanding the pharmacodynamic differences between various secretagogues is critical when designing growth factor axis assays. While CJC-1295 with DAC utilizes a maleimidopropionic acid linker to covalently bind serum albumin and extend half-life to several days, CJC-1295 (no DAC) exhibits a short plasma half-life of approximately 30 minutes, preserving endogenous pulsatility.
When compared to other compounds within the GHRH class, such as Sermorelin 5mg, CJC-1295 (no DAC) provides superior resistance to cleavage by DPP-IV, resulting in greater receptor occupancy per equivalent bio-assay concentration. Furthermore, combining GHRH analogs with selective ghrelin mimetics like Ipamorelin 5mg produces a synergistic effect in vitro, activating dual downstream pathways (GHRH-R and GHSR-1a) to amplify overall somatotroph output without triggering excessive cortisol or prolactin release. Detailed structural comparisons across secretagogue classes are archived in the PX1 Research Library.
To ensure reproducible quantitative measurements in cellular and molecular research, PX1 Research subjects every batch of CJC-1295 (no DAC) 5mg/vial to exhaustive analytical characterization. Purity is validated through Reverse-Phase High-Performance Liquid Chromatography (RP-HPLC), ensuring a minimum threshold of 99.0% chromatographic purity.
Mass spectrometry (ESI-MS) confirms precise molecular mass and sequence integrity, verifying the absence of truncated peptide fragments or deletion sequences. Additionally, endotoxin testing via Chromogenic LAL assay guarantees levels strictly under <0.5 EU/mg, preventing confounding inflammatory responses in sensitive cell cultures or animal research models.
• Sequence: Tyr-D-Ala-Asp-Ala-Ile-Phe-Thr-Gln-Ser-Tyr-Arg-Lys-Val-Leu-Ala-Gln-Leu-Ser-Ala-Arg-Lys-Leu-Leu-Gln-Asp-Ile-Leu-Ser-Arg-NH2 • Molecular Formula: C152H252N44O42 • Molecular Weight: 3367.2 g/mol • CAS Number: 863288-34-0 • Physical Form: Lyophilized white cake/powder • Purity: ≥99.0% (RP-HPLC) • Verification: Mass Spectrometry (MS) and Lot-Specific COA Included • Endotoxin Limit: <0.5 EU/mg
All analytical raw data files, including full-spectrum chromatograms, are made available to academic, clinical, and industrial procurement teams through our dedicated wholesale laboratory portal.
Reconstitution of lyophilized CJC-1295 (no DAC) 5mg/vial must be conducted under sterile laminar flow hoods using aseptic technique. To maintain peptide stability, researchers typically utilize Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Water for Injection, depending on experimental setup requirements.
Direct the solvent stream against the glass wall of the vial rather than directly onto the lyophilized powder cake to avoid agitation-induced aggregation. Gently swirl the vial until complete dissolution occurs; do not vortex. For detailed dilution math and volumetric concentration modeling, investigators should consult the PX1 Peptide Reconstitution Guide.
In vitro and animal models show that CJC-1295 (no DAC) plays a prominent role in investigating cellular regeneration, protein synthesis pathways, and lipid oxidation mechanisms. By stimulating intermittent GH pulses, researchers can evaluate the activation of hepatic STAT5b signaling pathways and the subsequent downstream expression of insulin-like growth factor 1 (IGF-1).
Preclinical studies suggest that elevated systemic IGF-1 levels downstream of GHRH activation promote collagen synthesis, skeletal muscle hypertrophy, and fibroblast proliferation. In tissue culture models of mechanical strain or ischemic insult, application of GHRH analogs has been associated with accelerated wound closure rates and enhanced extracellular matrix deposition.
Lyophilized CJC-1295 (no DAC) 5mg vials should be stored at -20°C upon receipt for long-term stability, protected from light exposure. Under these conditions, the un-reconstituted peptide remains stable for up to 24 months without significant degradation.
Once reconstituted into aqueous solution, aliquots should be maintained at 2°C to 8°C and used within 21 to 28 days. To prevent repeated freeze-thaw cycles—which cause mechanical peptide shear and degradation—reconstituted solutions intended for extended studies should be sub-aliquoted into single-use micro-centrifuge tubes and frozen at -80°C.
PX1 Research operates exclusively as a USA-based supplier of high-purity research compounds for institutional laboratories, universities, and contract research organizations (CROs). We do not supply products for human or veterinary administration; our full catalog of research peptides is intended strictly for in vitro laboratory research and preclinical testing.
Our facilities utilize ISO 17025 accredited laboratory workflows and state-of-the-art cGMP manufacturing protocols. Orders are packed in climate-controlled centers and shipped same-day (Monday through Friday) from fulfillment hubs in California and Arizona, ensuring minimal transit degradation and total chain-of-custody security.
What is cjc-1295 (no dac) 5mg/vial used for in a laboratory setting?
CJC-1295 (no dac) 5mg/vial is used as a reference standard in laboratory settings to study growth hormone-releasing hormone (GHRH) receptor binding, adenylate cyclase/cAMP signaling pathways, and pulsatile growth hormone and IGF-1 release mechanisms in cell cultures and animal models.
How does CJC-1295 (no DAC) differ structurally from CJC-1295 with DAC?
CJC-1295 (no DAC) is a 29-amino acid peptide without the Drug Affinity Complex linker. Lacking the maleimide group, it does not bind to serum albumin, resulting in a short physiological half-life (~30 minutes) that preserves natural, pulsatile hormone release.
What is the purity level of PX1 Research CJC-1295 (no DAC) 5mg vials?
Every lot of CJC-1295 (no DAC) 5mg/vial from PX1 Research is verified via RP-HPLC to meet or exceed 99.0% chromatographic purity, confirmed with mass spectrometry (ESI-MS) sequence verification.
Does PX1 Research supply a Certificate of Analysis (COA) with CJC-1295 (no DAC)?
Yes, every lot of CJC-1295 (no DAC) includes a downloadable, lot-specific Certificate of Analysis detailing HPLC purity chromatograms, mass spectrometry results, and LAL endotoxin testing values.
What solvent should be used to reconstitute CJC-1295 (no DAC) 5mg/vial?
For most analytical and laboratory applications, sterile Bacteriostatic Water (0.9% Benzyl Alcohol) or Sterile Normal Saline is used under aseptic conditions to dissolve the lyophilized powder.
How should reconstituted CJC-1295 (no DAC) solutions be stored?
Reconstituted liquid solutions should be stored at 2°C to 8°C (refrigerated) and utilized within 21–28 days. For longer storage, freeze micro-aliquots at -80°C to prevent freeze-thaw degradation.
What is the endotoxin limit for PX1 Research CJC-1295 (no DAC)?
PX1 Research enforces an endotoxin limit of <0.5 EU/mg on all CJC-1295 (no DAC) lots, verified using quantitative chromogenic LAL testing to prevent confounding inflammatory interference in assay models.
What receptor targets does CJC-1295 (no DAC) act upon?
CJC-1295 (no DAC) acts selectively as an agonist at the Growth Hormone-Releasing Hormone Receptor (GHRH-R) located on anterior pituitary somatotrophs.
Can CJC-1295 (no DAC) be combined with GHRP mimetics in research models?
Yes, preclinical literature frequently evaluates CJC-1295 (no DAC) in combination with GHSR agonists like Ipamorelin to investigate synergistic dual-receptor activation of growth hormone release pathways.
Where does PX1 Research ship CJC-1295 (no DAC) 5mg vials from?
All orders are fulfilled directly from our temperature-controlled facilities in California and Arizona, offering same-day dispatch for orders placed Monday through Friday before cut-off times.
All products are sold strictly for laboratory and research use only. Not for human or veterinary use, diagnosis, treatment or consumption. Statements have not been evaluated by the FDA.